Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this first episode, we discuss the evolution of therapy from chemotherapy to treatment with novel therapies such as enfortumab vedotin, or EV. We then focus on the key clinical trials examining the efficacy and safety of EV for the treatment of urothelial carcinoma.
Our Guests:
We introduce the topic in our first episode with Dr. Normand Blais, who is a medical oncologist and Director of clinical research in thoracic oncology at the CHUM and adjunct professor at McGill University in Montreal, QC.
Dr. Joel Claveau, a dermatologist specializing in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University guides us through this discussion.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.